Valuation: NetraMark Holdings Inc.

Market Cap 75.7M 53.96M 46.86M 43.56M 40.06M 5.15B 76.97M 514M 201M 2.57B 203M 198M 8.5B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 75.7M 53.96M 46.86M 43.56M 40.06M 5.15B 76.97M 514M 201M 2.57B 203M 198M 8.5B EV / Sales 2026 *
189x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
10/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
30/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
10/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
25/03 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
25/03 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
25/03 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day+3.34%
1 week+7.79%
1 month+42.79%
3 months-11.22%
6 months-28.20%
Current year-27.94%
1 week 0.55
Extreme 0.5545
0.57
1 month 0.46
Extreme 0.46
0.66
Current year 0.4
Extreme 0.4013
0.89
1 year 0.4
Extreme 0.4013
1.26
3 years 0.11
Extreme 0.114
1.26
5 years 0.1
Extreme 0.1045
1.61
10 years 0.1
Extreme 0.1045
1.61
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+3.34%+7.79% - - 53.96M
+3.02%+21.75%-12.89%+38.34% 3,451B
+0.65%+0.11%-22.29%+520.26% 295B
-0.22%+8.55%+91.43%+129.58% 95.39B
+2.16%+4.22%-6.73%+45.30% 93.64B
+4.41%+4.09%-38.63%-13.95% 74.44B
+0.47%+6.74%-31.86%+60.46% 65.38B
-1.82%+4.87%+9.06%+58.83% 45.4B
-26.85%-25.13%-74.16%-9.30% 25.43B
-0.79%+0.86%-30.60%-48.44% 30.53B
Average -1.56%+2.02%-12.96%+86.79% 464B
Weighted average by Cap. +2.48%+18.20%-12.05%+73.34%

Financials

2026 *2027 *
Net sales 401K 286K 248K 231K 212K 27.28M 408K 2.72M 1.07M 13.59M 1.07M 1.05M 45.01M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
29/07/26 USD 0.5730 +3.34% 2,000

Quarterly revenue - Rate of surprise